Paclitaxel-eluting stents

Authors: Cosgrave, John; Corbett, Simon; Babic, Rade; Colombo, Antonio

Source: Future Cardiology, Volume 2, Number 2, March 2006 , pp. 229-239(11)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.

Keywords: major adverse cardiac events; paclitaxel-eluting stent; restenosis; revascularization

Document Type: Research article

DOI: http://dx.doi.org/10.2217/14796678.2.2.229

Publication date: 2006-03-01

More about this publication?

Future Cardiology reflects the new era of cardiology and highlights new molecular approaches in advancing cardiovascular therapy. The journal publishes clinical research, commentary and therapeutic overviews highlighting optimal therapy and future options and strategies.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites